{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:25:16Z","timestamp":1787793916139,"version":"build-2784847793"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>For some people with migraine, despite taking greater amounts of acute headache medication (AHM), they develop an increase in monthly headache days. This cycle of increasing headache days, and in turn AHM use, can lead to a secondary headache disorder called medication-overuse headache (MOH). Preventive medications can prevent migraine from occurring and reduce reliance on AHMs, thereby preventing the cycle of MOH. This study was performed to evaluate the efficacy and safety of eptinezumab to prevent migraine\/headache in a mainly Asian patient population with a dual diagnosis of chronic migraine and MOH.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>SUNLIGHT was a phase 3, multicenter, double-blind, parallel-group, placebo-controlled trial. Patients aged 18\u221275\u00a0years with\u2009\u2265\u20098 migraine days\/month and a diagnosis of MOH were randomly allocated (1:1) to one of two treatment groups: eptinezumab 100\u00a0mg or placebo. Monthly migraine days (MMDs) were captured using a daily electronic diary; the change from baseline in the number of MMDs over Weeks 1\u221212 was the primary efficacy endpoint.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Patients were randomized to eptinezumab 100 mg (<jats:italic>n<\/jats:italic>\u2009=\u200993) or placebo (<jats:italic>n<\/jats:italic>\u2009=\u2009100). Over Weeks 1\u221212, eptinezumab reduced mean MMDs more than placebo (difference between treatments was -1.2; <jats:italic>p<\/jats:italic>\u2009=\u20090.1484). Differences between treatment groups with p-values below 0.05 favoring eptinezumab were observed in 3 out of the 6 key secondary endpoints.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>All endpoints numerically favored eptinezumab treatment when compared to placebo; however, this study did not meet its primary endpoint and is therefore negative. No new safety signals were identified in this study, like previous reports that confirmed the safety and tolerability of eptinezumab treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov identifier: NCT04772742 (26\/02\/2021).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-023-03477-z","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T08:02:16Z","timestamp":1702627336000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and safety of eptinezumab in patients with chronic migraine and medication-overuse headache: a randomized, double-blind, placebo-controlled study"],"prefix":"10.1186","volume":"23","author":[{"given":"Shengyuan","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guogang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheman","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Ettrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Jansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Florea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Ranc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pozo-Rosich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,15]]},"reference":[{"issue":"19","key":"3477_CR1","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M Ashina","year":"2020","unstructured":"Ashina M. Migraine. N Engl J Med. 2020;383(19):1866\u201376. https:\/\/doi.org\/10.1056\/NEJMra1915327.","journal-title":"N Engl J Med"},{"key":"3477_CR2","doi-asserted-by":"publisher","unstructured":"Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018; 17(11):954\u201376. https:\/\/doi.org\/10.1016\/s1474-4422(18)30322-3.","DOI":"10.1016\/s1474-4422(18)30322-3"},{"issue":"9995","key":"3477_CR3","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/s0140-6736(15)60692-4","volume":"386","author":"Collaborators GBoDS","year":"2015","unstructured":"Collaborators GBoDS. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743\u2013800. https:\/\/doi.org\/10.1016\/s0140-6736(15)60692-4.","journal-title":"Lancet"},{"key":"3477_CR4","doi-asserted-by":"publisher","unstructured":"Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459\u201380. https:\/\/doi.org\/10.1016\/s1474-4422(18)30499-x.","DOI":"10.1016\/s1474-4422(18)30499-x"},{"key":"3477_CR5","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202.","DOI":"10.1177\/0333102417738202"},{"issue":"9","key":"3477_CR6","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/head.13407","volume":"58","author":"RB Lipton","year":"2018","unstructured":"Lipton RB, Munjal S, Alam A, Buse DC, Fanning KM, Reed ML, et al. Migraine in America Symptoms and Treatment (MAST) Study: baseline study methods, treatment patterns, and gender differences. Headache. 2018;58(9):1408\u201326. https:\/\/doi.org\/10.1111\/head.13407.","journal-title":"Headache"},{"issue":"1","key":"3477_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s10194-020-1084-y","volume":"21","author":"DC Buse","year":"2020","unstructured":"Buse DC, Reed ML, Fanning KM, Bostic R, Dodick DW, Schwedt TJ, et al. Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study. J Headache Pain. 2020;21(1):23. https:\/\/doi.org\/10.1186\/s10194-020-1084-y.","journal-title":"J Headache Pain"},{"issue":"1","key":"3477_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/head.14036","volume":"61","author":"HC Diener","year":"2021","unstructured":"Diener HC, Marmura MJ, Tepper SJ, Cowan R, Starling AJ, Diamond ML, et al. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2. Headache. 2021;61(1):125\u201336. https:\/\/doi.org\/10.1111\/head.14036.","journal-title":"Headache"},{"issue":"5","key":"3477_CR9","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/jnnp-2014-308548","volume":"86","author":"ES Kristoffersen","year":"2015","unstructured":"Kristoffersen ES, Straand J, Vetvik KG, Benth J, Russell MB, Lundqvist C. Brief intervention for medication-overuse headache in primary care. The BIMOH study: a double-blind pragmatic cluster randomised parallel controlled trial. J Neurol Neurosurg Psychiatry. 2015;86(5):505\u201312. https:\/\/doi.org\/10.1136\/jnnp-2014-308548.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"22","key":"3477_CR10","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1212\/01.wnl.0000335946.53860.1d","volume":"71","author":"ME Bigal","year":"2008","unstructured":"Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology. 2008;71(22):1821\u20138. https:\/\/doi.org\/10.1212\/01.wnl.0000335946.53860.1d.","journal-title":"Neurology"},{"issue":"7","key":"3477_CR11","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/ene.14268","volume":"27","author":"HC Diener","year":"2020","unstructured":"Diener HC, Antonaci F, Braschinsky M, Evers S, Jensen R, Lainez M, et al. European Academy of Neurology guideline on the management of medication-overuse headache. Eur J Neurol. 2020;27(7):1102\u201316. https:\/\/doi.org\/10.1111\/ene.14268.","journal-title":"Eur J Neurol"},{"issue":"1","key":"3477_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s10194-016-0678-x","volume":"17","author":"H Jiang","year":"2016","unstructured":"Jiang H, Deng Y, Zhang Y, Jin J, Kong X, Zhu Q, et al. Field testing of the ICHD-3\u03b2 and expert opinion criteria for chronic migraine. J Headache Pain. 2016;17(1):85. https:\/\/doi.org\/10.1186\/s10194-016-0678-x.","journal-title":"J Headache Pain"},{"key":"3477_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jocn.2017.10.066","volume":"48","author":"J Li","year":"2018","unstructured":"Li J, Chen C, Zhang L, Cui X, Wei C, Diao X. Analysis on the risk factors of medication-overuse headache in Chinese patients. J Clin Neurosci. 2018;48:153\u20139. https:\/\/doi.org\/10.1016\/j.jocn.2017.10.066.","journal-title":"J Clin Neurosci."},{"issue":"5","key":"3477_CR14","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1468-1331.2011.03612.x","volume":"19","author":"M Linde","year":"2012","unstructured":"Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barr\u00e9 J, Katsarava Z, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012;19(5):703\u201311. https:\/\/doi.org\/10.1111\/j.1468-1331.2011.03612.x.","journal-title":"Eur J Neurol"},{"issue":"7","key":"3477_CR15","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1177\/0333102411398400","volume":"31","author":"M Lanteri-Minet","year":"2011","unstructured":"Lanteri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia. 2011;31(7):837\u201350. https:\/\/doi.org\/10.1177\/0333102411398400.","journal-title":"Cephalalgia"},{"issue":"9","key":"3477_CR16","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1007\/s00415-017-8434-y","volume":"264","author":"F Puledda","year":"2017","unstructured":"Puledda F, Messina R, Goadsby PJ. An update on migraine: current understanding and future directions. J Neurol. 2017;264(9):2031\u20139. https:\/\/doi.org\/10.1007\/s00415-017-8434-y.","journal-title":"J Neurol"},{"key":"3477_CR17","unstructured":"VYEPTI [package insert]. Bothell: Lundbeck Seattle BioPharmaceuticals, Inc.; 2021."},{"issue":"3","key":"3477_CR18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/0333102418821662","volume":"39","author":"DW Dodick","year":"2019","unstructured":"Dodick DW. CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications. Cephalalgia. 2019;39(3):445\u201358. https:\/\/doi.org\/10.1177\/0333102418821662.","journal-title":"Cephalalgia"},{"issue":"3","key":"3477_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, Schaeffler B, Biondi DM, Hirman J, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40(3):241\u201354. https:\/\/doi.org\/10.1177\/0333102420905132.","journal-title":"Cephalalgia"},{"issue":"15 Supplement","key":"3477_CR20","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1212\/WNL.94.15_supplement.541","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Dodick DW, Ailani J, Winner P, Hindiyeh NA, Hirman J, et al. Patient-identified most bothersome symptom in patients with chronic migraine: an analysis of PROMISE-2 (541). Neurology. 2020;94(15 Supplement):541.","journal-title":"Neurology"},{"issue":"7","key":"3477_CR21","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","volume":"21","author":"M Ashina","year":"2022","unstructured":"Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen CL, Josiassen MK, et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022;21(7):597\u2013607.","journal-title":"Lancet Neurol"},{"issue":"9","key":"3477_CR22","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1111\/head.14206","volume":"61","author":"MJ Marmura","year":"2021","unstructured":"Marmura MJ, Diener HC, Cowan RP, Tepper SJ, Diamond ML, Starling AJ, et al. Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache. Headache. 2021;61(9):1421\u201331. https:\/\/doi.org\/10.1111\/head.14206.","journal-title":"Headache"},{"issue":"2","key":"3477_CR23","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/head.14434","volume":"63","author":"AJ Starling","year":"2023","unstructured":"Starling AJ, Cowan RP, Buse DC, Diener HC, Marmura MJ, Hirman J, et al. Eptinezumab improved patient-reported outcomes in patients with migraine and medication-overuse headache: Subgroup analysis of the randomized PROMISE-2 trial. Headache. 2023;63(2):264\u201374. https:\/\/doi.org\/10.1111\/head.14434.","journal-title":"Headache"},{"issue":"2","key":"3477_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.567","volume":"8","author":"B Baker","year":"2020","unstructured":"Baker B, Schaeffler B, Beliveau M, Rubets I, Pederson S, Trinh M, et al. Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine. Pharmacol Res Perspect. 2020;8(2): e00567. https:\/\/doi.org\/10.1002\/prp2.567.","journal-title":"Pharmacol Res Perspect"},{"key":"3477_CR25","doi-asserted-by":"crossref","unstructured":"Baker B, Schaeffler BA, Cady RK, Latham JA, Whitaker T, Smith JTL. Rational Design of a Monoclonal Antibody (mAb) Inhibiting Calcitonin Gene-Related Peptide (CGRP), ALD403, Intended for the Prevention of Migraine (P2.155). Neurology. 2017;88.","DOI":"10.1212\/WNL.88.16_supplement.P2.155"},{"issue":"10","key":"3477_CR26","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102420941839","volume":"40","author":"HC Diener","year":"2020","unstructured":"Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia. 2020;40(10):1026\u201344. https:\/\/doi.org\/10.1177\/0333102420941839.","journal-title":"Cephalalgia"},{"key":"3477_CR27","unstructured":"Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education, and Welfare Publication (ADM). Rockville, MD: National Institute of Mental Health. 1976, pp. 76-338."},{"issue":"5","key":"3477_CR28","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/head.14120","volume":"61","author":"RB Lipton","year":"2021","unstructured":"Lipton RB, Dodick DW, Ailani J, McGill L, Hirman J, Cady R. Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: a novel patient-centered outcome. Headache. 2021;61(5):766\u201376. https:\/\/doi.org\/10.1111\/head.14120.","journal-title":"Headache"},{"issue":"7","key":"3477_CR29","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"Ailani J, Burch RC, Robbins MS, on behalf of the Board of Directors of the American Headache Society","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS, on behalf of the Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021\u201339. https:\/\/doi.org\/10.1111\/head.14153.","journal-title":"Headache"},{"issue":"5","key":"3477_CR30","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365. https:\/\/doi.org\/10.2165\/00019053-199304050-00006.","journal-title":"Pharmacoeconomics"},{"issue":"13","key":"3477_CR31","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/wnl.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020;94(13):e1365\u201377. https:\/\/doi.org\/10.1212\/wnl.0000000000009169.","journal-title":"Neurology"},{"issue":"1","key":"3477_CR32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-022-00415-0","volume":"9","author":"S Ashina","year":"2023","unstructured":"Ashina S, Terwindt GM, Steiner TJ, Lee MJ, Porreca F, Tassorelli C, et al. Medication overuse headache. Nat Rev Dis Primers. 2023;9(1):5. https:\/\/doi.org\/10.1038\/s41572-022-00415-0.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"3477_CR33","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1468-2982.2008.01711.x","volume":"29","author":"K Hagen","year":"2009","unstructured":"Hagen K, Albretsen C, Vilming ST, Salvesen R, Gr\u00f8nning M, Helde G, et al. Management of medication overuse headache: 1-year randomized multicentre open-label trial. Cephalalgia. 2009;29(2):221\u201332. https:\/\/doi.org\/10.1111\/j.1468-2982.2008.01711.x.","journal-title":"Cephalalgia"},{"issue":"9","key":"3477_CR34","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamaneurol.2020.1179","volume":"77","author":"LN Carlsen","year":"2020","unstructured":"Carlsen LN, Munksgaard SB, Nielsen M, Engelstoft IMS, Westergaard ML, Bendtsen L, et al. Comparison of 3 Treatment Strategies for Medication Overuse Headache: A Randomized Clinical Trial. JAMA Neurol. 2020;77(9):1069\u201378. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1179.","journal-title":"JAMA Neurol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03477-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-023-03477-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03477-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T08:03:34Z","timestamp":1702627414000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-023-03477-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3477"],"URL":"https:\/\/doi.org\/10.1186\/s12883-023-03477-z","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,15]]},"assertion":[{"value":"28 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with standards of Good Clinical Practice as defined by the International Conference on Harmonisation and all applicable federal and local regulations. All study documentation was approved by the local review board at each site or by a central institutional review board\/ethics committee; there were a total of 40 sites: The First Affiliated Hospital of Guangzhou Medical University (Guangzhou, Guangdong, China, 510120), Beijing Chaoyang Hospital Capital Medical University (Beijing, China, 100020), Beijing Anzhen Hospital, Capital Medical University (Beijing, China, 100029), Peking University First Hospital (Beijing, China, 100034), Xuanwu Hospital Capital Medical University (Beijing, China, 100053), Peking Union Medical College Hospital (Beijing, China, 100730), Chinese PLA General Hospital (Beijing, China, 100853), Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University) (Beijing, China, 610041), The First Hospital of Jilin University (Changchun, China, 130021), The Second Hospital of Jilin University (Changchun, China, 130022), The First Affiliated Hospital of Chongqing Medical University (Chongqing, China, 400016), The Affiliated Hospital of Guizhou Medical University (Guiyang, China, 550000), Mianyang Central Hospital (Mianyang, China, 621000), Jiangxi Pingxiang People's Hospital (Pingxiang, China, 337055), People's Hospital of Rizhao (Rizhao, China, 276826), Shengjing Hospital of China Medical University (Shenyang, China, 110004), General Hospital of Northern Theater Command (Shenyang, China, 110015), The University of Hong Kong\u2014Shenzhen Hospital (Shenzhen, China, 518053), Shanxi Provincial People Hospital (Taiyuan, China, 030012), The 2nd Affiliated Hospital of Wenzhou Medical University (Wenzhou, China, 325035), Union Hospital Tongji Medical College Huazhong University of Science and Technology (Wuhan, China, 430022), Renmin Hospital of Wuhan University (Wuhan, China, 430060), The First Affiliated Hospital of Xi'an Jiaotong University (Xi'an, China, 710061), People's Hospital of Zhengzhou (Zhengzhou, China, 450003), The First Affiliated Hospital of Zhengzhou University (Zhengzhou, China, 450052), Affiliated Hospital of Jiangsu University (Zhenjiang, China, 212001), Pineo Medical Ecosystem (Tbilisi, Georgia, 0114), Aversi Clinic LTD (Tbilisi, Georgia, 0160), Nowon Eulji Medical Center, Eulji University (Seoul, Korea, Republic of, 01830), Severance Hospital Yonsei University Health System\u2014PPDS (Seoul, Korea, Republic of, 03722), Samsung Medical Center\u2014PPDS (Seoul, Korea, Republic of, 06351), Hospital Universitario Puerta de Hierro\u2014Majadahonda (Majadahonda, Madrid, Spain, 28222), Hospital Universitario Vall d'Hebron\u2014PPDS (Barcelona, Spain, 8035), Hospital Universitario La Paz\u2014PPDS (Madrid, Spain, 28046), Hospital Clinico Universitario de Valencia (Valencia, Spain, 46010), Hospital Universitari i Politecnic La Fe de Valencia (Valencia, Spain, 46026), Hospital Clinico Universitario Lozano Blesa (Zaragoza, Spain, 50009), Taipei Veterans General Hospital (Taipei City, Taiwan, 11217), Tri-Service General Hospital (Taipei, Taiwan, 11490), Chang Gung Memorial Hospital, Linkou (Taoyuan City, Taiwan, 33305). All patients provided written informed consent prior to their participation in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SY, JZ, GL, and ZX disclose no conflicts of interest. AE, GJ, KR, and IF are full-time employees of H. Lundbeck A\/S. PPR reports honoraria as a consultant and participation in the last 3\u00a0years in advisory boards for AbbVie, Amgen, Biohaven, Chiesi, Eli Lilly, Lundbeck, Novartis, Pfizer, and Teva Pharmaceuticals; institutional research support from AbbVie, AGAUR, ERA-NET NEURON, Instituto Investigaci\u00f3n Carlos III, International Headache Society, Novartis, PERIS, RIS3CAT FEDER, and Teva Pharmaceuticals; being a principle investigator for more than 45 clinical trials (phase II, III, and IV) for the preventive treatment of migraine and other headaches; education projects with AbbVie, Almirall, Chiesi, Eli Lilly, Lundbeck, Medlink, Medscape, Neurodiem, Novartis, and Teva Pharmaceuticals; participation in the Scientific Advisory Board of Lilly Foundation Spain and Honorary Secretary of the International Headache Society; and being an associate editor for <i>Cephalalgia, Headache, Neurologia, Frontiers of Neurology<\/i>, director for headache section of <i>Revista de Neurologia<\/i>, and editorial advisor for <i>Journal of Headache and Pain<\/i>.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"441"}}